Imatinib and gastrointestinal stromal tumors: Where do we go from here?

Molecular Cancer Therapeutics

Volumn 4, Issue 3, 2005, Pages 495-501

  De Giorgi, Ugo ^a   Verweij, Jaap ^b  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DNA; ERYTHROPOIETIN; EVEROLIMUS; FLT3 LIGAND; FLUORODEOXYGLUCOSE F 18; FLUOXETINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HYPERICUM PERFORATUM EXTRACT; IMATINIB; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; OBLIMERSEN; OROSOMUCOID; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE C THETA; PROTEIN TYROSINE KINASE; RADIOISOTOPE; RIFAMPICIN; SIMVASTATIN; SUNITINIB; UNINDEXED DRUG; WARFARIN;

ANEMIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; EDEMA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; MEDICAL SPECIALIST; MOLECULAR MECHANICS; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RASH; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; ONCOGENE PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TIME FACTORS;

EID: 15944379625     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (70)

1. De Matteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
3. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33: 459-65.
4. De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence pattern and prognostic factors for survival. Ann Surg 2000;231:51-8.
5. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001;54:96-102.
6. Kindblom L-G, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
7. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
8. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998;279:577-80.
9. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
10. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7.
11. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
12. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
13. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8.
14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with metastatic gastrointestinal stromal tumour. N Engl J Med 2001;344:1052-6.
15. van Oosterom AT, Judson I, Verweiji J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
16. van Oosterom AT, Judson IR, Verweij J, et al. Update of a phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38 Suppl 5:S83-7.
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
18. Verweij J, van Oosterom A, Blay J-Y, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006-11.
19. Rankin C, Von Mehren M, Blanke C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2004;23:815. (abstr 9005).
20. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
21. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8.
22. Blay J-Y, Berthaud P, Perol D, et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 2004;23:815. (abstr 9006).
23. + gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003;186:665-9.
24. Dileo P, Randhawa R, Vansonnenberg E, et al. Safety and efficacy of percutaneous radio-frequency ablation in patients with metastatic gastrointestinal stromal tumor with clonal evolution of lesions refractory to imatinib mesylate. Proc Am Soc Clin Oncol 2004;23:9024.
25. Duffaud F, Lecesne A, Ray-Coquard I, et al. Erythropoietin for anemia treatment of patients with GIST receiving imatinib. Proc Am Soc Clin Oncol 2004;23:825. (abstr 9046).
26. Heim D, Ebnöther M, Meyer-Monard S, et al. G-CSF for imatinib-induced neutropenia. Leukemia 2003;17:805-7.
27. Novartis Pharmaceutical Corporation. Gleevec (imatinib mesylate) prescribing information. Novartis Pharmaceuticals Corporation, NJ, USA, 2004. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf. Accessed February 2005.
28. de Jong FA, Verweij J. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. Expert Rev Anticancer Ther 2003;3: 757-66.
29. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-4.
30. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. Induction of imatinib metabolism by hypericum perforatum. Blood 2004;104:1229-30.
31. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-6.
32. Fryem RF, Fitzgeraldm SM, Lagattutam TF, Hruskam MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-9.
33. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003;89:1855-9.
34. Ramanathan RK, Remick SC, Mulkerin D, et al. P-5331: a phase I pharmacokinetic study of STI571 in patients with advanced malignancies and varying degrees of liver dysfunction. Proc Am Soc Clin Oncol 2003;22:126. (abstr 502).
35. Remick SC, Ramanathan RK, Mulkerin D, et al. P-5340: a phase I pharmacokinetic study of STI571 in patients with advanced malignancies and varying degrees of renal dysfunction. Proc Am Soc Clin Oncol 2003;22:126. (abstr 503).
36. Judson IR, Donato Di Paola E, Verweij J, et al. Population pharmacokinetics (PK) analysis and PK-pharmacodynamic (PD) correlations in phase I/II trial of imatinib in gastrointestinal stromal tumours (GIST) conducted by the European Organisation for Research and Treatment Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol Epub 2004 Dec 9.
37. Delbaldo C, Chatelut E, Rè M, et al. Inflammatory response affects the pharmacokinetics and pharmacodynamics of imatinib and CGP 74588 in patients with advanced gastro-intestinal-sarcoma (GIST). Proc Am Soc Clin Oncol 2004;23:144. (abstr 2070).
38. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4: 224-32.
39. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23:3999-4006.
40. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
41. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998;19:323-4.
42. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-95.
43. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
44. Corless LC, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
45. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
46. Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004;15:3282-90.
47. Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003;2:699-709.
48. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-94.
49. Bauer S, Corless CL, Heinrich MC, et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003;51:261-5.
50. Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal tumor. Proc Am Soc Clin Oncol 2003;22:815. (abstr 3275).
51. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45.
52. Burger H, Van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2.
53. Hohenberger P, Bauer S, Schneider U, et al. Tumor resection following imatinib pretreatment in GI stromal tumors. Proc Am Soc Clin Oncol 2003;21:3288a.
54. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004;103:523-9.
55. Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527-32.
56. Casali PG, Fumagalli E, Messina A, et al. Tumor response to imatinib mesylate in advanced GIST. Proc Am Soc Clin Oncol 2004;23:821. (abstr 9028).
57. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with gastrointestinal stromal tumor (GIST): molecular and radiological evaluation of new lesions. Proc Am Soc Clin Oncol 2004;23:197. (abstr 3010).
58. Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2003;2:419-26.
59. Blasberg RG. Molecular imaging and cancer. Mol Cancer Ther 2003;2:335-43.
60. Lassau N, Lamuraglia M, Leclère J, et al. Doppler-ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: results of a prospective study. Proc Am Soc Clin Oncol 2004;23:826. (abstr 9048).
61. De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M. Effect of angio-sonography with a second generation contrast agent to assess tumor response to imatinib treatment in patients with advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2004;23:366. (abstr 4216).
62. Subramanian S, West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004;23:7780-90.
63. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107-13.
64. Blay P, Astudillo A, Buesa JM, et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 2004;10:4089-95.
65. Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004;114:379-88.
66. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib orally versus intravenous infusion. J Clin Pharmacol 2004;44: 158-62.
67. Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Eur J Nucl Med Mol Imaging 2003;30:463-9.
68. Demetri GO, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2004;23:195. (abstr 3001).
69. Van Oosterom AT, Dumez H, Desai J, et al. Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (RAD001) and imatinib mesylate in patients with gastrointestinal stromal tumor (GIST) refractory to IM. Proc Am Soc Clin Oncol 2004;23:195. (abstr 3002).
70. National Cancer Institute Clinical Trials. [cited 2005 Feb]. Available from: http://cancer.gov/search/ ResultsClinicalTrials.aspx?protocol-searchid=1428474